New research indicates that people who come off new GLP-1 drugs like semaglutide or tirzepatide tend to recover lost weight at a significantly accelerated pace than those who end traditional diet and exercise plans.
Published data in a major health publication points out that while overweight people frequently drop substantial amounts of their body weight while on the medication, the mass returns at an average rate of nearly a kilo each month once they quit.
"Individuals purchasing such treatments need to be informed of the risk of rapid rebound weight gain when the therapy concludes," cautioned lead investigator Dr. Susan Jebb.
This pace of recovery means a reversion to pre-treatment mass within about 18 months.
Comparing Therapies
The research, which looked at 37 of trials involving thousands of participants, compared the effects of GLP-1 agonists with conventional dieting.
Scientists emphasize that people who shed pounds through lifestyle changes alone generally have a less rapid weight regain—approximately 0.1 kg a month—post-intervention.
The Reason for the Fast Rebound
Nutrition scientists believe the mechanism of the injections accounts for the heightened regain.
GLP-1 drugs imitate a natural hormone called glucagon-like peptide-1, which moderates appetite.
"Long-term administration of GLP-1 levels far above than normal might result in the system to produce less of its own natural hormone, and could diminish sensitivity to its actions," noted Dr. Adam Collins, a nutrition expert.
"Discontinuation of this medication leads to hunger is unsuppressed, making binge eating a significant risk."
A Lifelong Disease?
Health authorities recommend the jabs for people with weight-linked health risks, accompanied by recommended diet and exercise modifications.
A number of clinicians say that, given the high risk of relapse, the treatment might need to be ongoing.
This perspective is echoed by pharmaceutical companies, who say that the findings "underscore the chronic nature of excess weight," similar to managing diseases like diabetes.
Patient Experiences
People who have stopped the medication report a powerful return of hunger.
"I experienced a trigger activating and you become ravenous," said an individual.
This challenge is compounded if users have not established lasting dietary or behavioural changes during therapy.
Growing Adoption
Survey data show that millions of people in the UK have tried these injections in the past year, with interest being substantial.
- Use is higher among women than males.
- The 40s and 50s demographic shows the highest usage rates.
- A large proportion obtain the medications through private healthcare rather than public health services.
Finally, clinicians stress that while GLP-1 drugs are powerful tools for weight loss, they are not a magic cure and long-term success likely depends on combined lifestyle management.
